{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462248957
| IUPAC_name = 5-Amino-2-hydroxybenzoic acid
| image = Mesalazine structure.svg
| width = 171
<!--Clinical data-->
| tradename = Many names worldwide, including Azacol, Lialda, Pentasa, and Apriso<ref name=generics>Drugs.com [https://www.drugs.com/ingredient/mesalamine.html International trade names for mesalazine] April 20, 2016</ref>
| Drugs.com = {{drugs.com|monograph|mesalamine}}
| pregnancy_US = B
| pregnancy_category =
| legal_US = Rx-only
| legal_status =
| routes_of_administration = oral, [[rectal|rectal]]
| licence_US = Mesalazine
| MedlinePlus = a688021
| DailyMedID = 47586
<!--Pharmacokinetic data-->
| bioavailability = orally: 20–30% absorbed<br>rectally: 10–35%
| metabolism = Rapidly & extensively metabolised intestinal mucosal wall and the liver
| elimination_half-life = 5 hours after initial dose.<br>At steady state 7 hours
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89-57-6
| ATC_prefix = A07
| ATC_suffix = EC02
| PubChem = 4075
| IUPHAR_ligand = 2700
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00244
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3933
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4Q81I59GXC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00377
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6775
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 704
<!--Chemical data-->
| C=7 | H=7 | N=1 | O=3
| molecular_weight = 153.135 g/mol
| smiles = O=C(O)c1cc(ccc1O)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KBOPZPXVLCULAV-UHFFFAOYSA-N
}}
{{medical}}

'''美沙拉嗪'''（{{Lang-en|Mesalazine}}，又名'''美沙拉秦'''，'''5'-氨基水杨酸（5-ASA）'''），是一种氨基水杨酸类抗炎药<ref>{{Cite web|url=http://www.pharmgkb.org/drug/PA450384#tabview=tab2&subtab=31|title=PharmGKB|accessdate=2018-07-21|work=PharmGKB|language=en}}</ref>，用于治疗炎性肠病，包括[[溃疡性结肠炎|溃疡性结肠炎]]<ref name=":0">{{Cite web|url=http://www.medicines.org.uk/emc/medicine/12583|title=Asacol 400mg MR Tablets - Summary of Product Characteristics (SmPC) - (eMC)|accessdate=2018-07-21|work=www.medicines.org.uk|language=en}}</ref><ref name=":1">{{Cite web|url=http://www.medicines.org.uk/emc/medicine/11571|title=Asacol 250mg Suppositories - Summary of Product Characteristics (SmPC) - (eMC)|accessdate=2018-07-21|work=www.medicines.org.uk|language=en}}</ref>，[[直肠炎|直肠炎]]，[[克罗恩病|克罗恩病]]等<ref name=":0" /><ref>{{Cite journal|title=Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission|url=https://www.ncbi.nlm.nih.gov/pubmed/17877506|last=Sandborn|first=W. J.|last2=Feagan|first2=B. G.|date=2007-10-01|journal=Alimentary Pharmacology & Therapeutics|issue=7|doi=10.1111/j.1365-2036.2007.03455.x|volume=26|pages=987–1003|issn=0269-2813|pmid=17877506|last3=Lichtenstein|first3=G. R.}}</ref>。

美沙拉嗪以口服形式服用缓解克罗恩病<ref name=":0" />，此外亦能以直肠栓剂或灌肠剂形式治疗下肠道疾病<ref name=":1" />。

没有孕妇使用的数据，但药物确实能穿过胎盘并通过母乳排出体外。该药不应用于2岁以下儿童，肾病患者或对阿司匹林过敏的人<ref name=":1" />。

主要副作用是胃肠道反应，包括恶心，腹泻和腹痛，此外也可能出现头痛。当口服用药时，有各种不良反应的分散报告，包括：[[骨髓抑制|骨髓抑制]]（白细胞减少，中性粒细胞减少，[[粒细胞缺乏症|粒细胞缺乏症]]，[[再生障碍性贫血|再生障碍性贫血]]和血小板减少症），以及[[脱发|脱发]]，[[周围神经病|周围神经病]]，[[胰腺炎|胰腺炎]]，肝脏问题，[[心肌炎|心肌炎]]。还包括[[心包炎|心包炎]]，过敏反应和[[肺纖維化|肺纤维化]]反应，[[紅斑狼瘡|红斑狼疮]]样反应和[[皮疹|皮疹]]（包括[[荨麻疹|荨麻疹]]），[[发热|药物热]]，[[間質性腎炎|间质性肾炎]]和[[肾炎综合征|肾病综合征]]，通常在停药时可逆。很少出现服用美沙拉嗪与结肠炎，[[史蒂文斯约翰逊综合征|史蒂文斯约翰逊综合征]]和[[多形性红斑|多形性红斑]]的症状恶化相关不良反应。

美沙拉嗪是[[柳氮磺胺吡啶|柳氮磺胺吡啶]]的活性部分，其在体内代谢为磺胺吡啶和美沙拉嗪。它也是前体药巴柳氮以及惰性载体分子4-氨基苯甲酰基-β-丙氨酸的活性成分。

== 参考文献 ==
<references />{{止泻药、肠道抗炎/抗感染药}}

[[Category:苯胺|Category:苯胺]]
[[Category:抗炎药|Category:抗炎药]]
[[Category:抗氧化剂|Category:抗氧化剂]]
[[Category:水杨酸|Category:水杨酸]]